Related references
Note: Only part of the references are listed.Impact of Infectious Disease Consultation on Clinical Management and Mortality in Patients With Candidemia
Rachael A. Lee et al.
CLINICAL INFECTIOUS DISEASES (2019)
Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study
C. A. Gentry et al.
CLINICAL MICROBIOLOGY AND INFECTION (2019)
Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan
Hiroshige Mikamo et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2018)
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial
Benoit Guery et al.
LANCET INFECTIOUS DISEASES (2018)
An Antimicrobial Stewardship Program Based on Systematic Infectious Disease Consultation in a Rehabilitation Facility
Sara Tedeschi et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2017)
A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection
Hannah E. Burton et al.
PHARMACOECONOMICS (2017)
Infectious disease consultation for Staphylococcus aureus bacteremia - A systematic review and meta-analysis
Monique Vogel et al.
JOURNAL OF INFECTION (2016)
Clinical and Economic Benefits of Fidaxomicin Compared to Vancomycin for Clostridium difficile Infection
Jason C. Gallagher et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
A Multi-Center Prospective Derivation and Validation of a Clinical Prediction Tool for Severe Clostridium difficile Infection
Xi Na et al.
PLOS ONE (2015)
Performance of Clostridium difficile Toxin Enzyme Immunoassay and Nucleic Acid Amplification Tests Stratified by Patient Disease Severity
Romney M. Humphries et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2013)
Fidaxomicin Inhibits Spore Production in Clostridium difficile
Farah Babakhani et al.
CLINICAL INFECTIOUS DISEASES (2012)
Fidaxomicin Attains High Fecal Concentrations With Minimal Plasma Concentrations Following Oral Administration in Patients With Clostridium difficile Infection
Pamela Sears et al.
CLINICAL INFECTIOUS DISEASES (2012)
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
Oliver A. Cornely et al.
LANCET INFECTIOUS DISEASES (2012)
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Thomas J. Louie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin
Gerald W. Tannock et al.
MICROBIOLOGY-SGM (2010)
OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C-difficile Infection
Thomas J. Louie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system
Jaime Belmares et al.
JOURNAL OF INFECTION (2007)
In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004
David W. Hecht et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Recommendations for surveillance of Clostridium difficile-associated disease
L. Clifford McDonald et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2007)
Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species
KL Credito et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Share Paper
